Last updated on February 2018

The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Polycystic Ovary Syndrome | Obesity | Overweight
  • Age: Between 14 - 50 Years
  • Gender: Female

Inclusion Criteria:

  • Clinical diagnosis of PCOS according to the Rotterdam criteria based on the presence of two of three criteria: oligomenorrhoea, clinical or biochemical hyperandrogenism and polycystic ovaries on ultrasound after exclusion of other endocrine causes of hyperandrogenism.
  • Participants had no concurrent illness and were not on any prescription or over-the-counter medication that was likely to affect insulin sensitivity or lipids for the preceding 12 weeks.
  • Participants were advised not to change physical activity or dietary habits during the study period. All subjects were overweight/obese [body mass index (BMI) >=24 kg/m2 or waistline>=85cm ].
  • All subjects had normal thyroid-stimulating hormone and prolactin levels.

Exclusion Criteria:

  • smoking, alcohol use, or having taken medication within 2 months of the study that is known to affect reproductive or metabolic functions.
  • age below 14 yr or over 50 yr.
  • postmenopausal.
  • uncontrolled hypertension (blood pressure >=160/100 mm Hg).
  • preexisting OPs or GLP-1 agonists supplementation
  • alcohol intake greater than 20 g/d, or pregnancy.
  • signs of liver or renal failure or active liver disease (ALT > 2.5 the upper limit of normal values).
  • PLT<60*10^9/L,Hb<100g/L, smoking, alcohol use.
  • The patient that cannot complete the intervention or have other conditions that is not appropriate to enter the group, such as patients who are taking glucocorticoid steroids or malignant tumor treatment, etc.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.